Passa ai contenuti principali

Effetto di aspirina quotidianamente sul rischio a lungo termine di morte per cancro: l'analisi dei dati di singoli pazienti degli studi randomizzati


Background

Treatment with daily aspirin for 5 years or longer reduces subsequent risk of colorectal cancer. Several lines of evidence suggest that aspirin might also reduce risk of other cancers, particularly of the gastrointestinal tract, but proof in man is lacking. We studied deaths due to cancer during and after randomised trials of daily aspirin versus control done originally for prevention of vascular events.


Methods

We used individual patient data from all randomised trials of daily aspirin versus no aspirin with mean duration of scheduled trial treatment of 4 years or longer to determine the effect of allocation to aspirin on risk of cancer death in relation to scheduled duration of trial treatment for gastrointestinal and non-gastrointestinal cancers. In three large UK trials, long-term post-trial follow-up of individual patients was obtained from death certificates and cancer registries.

Results

In eight eligible trials (25 570 patients, 674 cancer deaths), allocation to aspirin reduced death due to cancer (pooled odds ratio [OR] 0·79, 95% CI 0·68—0·92, p=0·003). On analysis of individual patient data, which were available from seven trials (23 535 patients, 657 cancer deaths), benefit was apparent only after 5 years' follow-up (all cancers, hazard ratio [HR] 0·66, 0·50—0·87; gastrointestinal cancers, 0·46, 0·27—0·77; both p=0·003). The 20-year risk of cancer death (1634 deaths in 12 659 patients in three trials) remained lower in the aspirin groups than in the control groups (all solid cancers, HR 0·80, 0·72—0·88, p<0·0001; gastrointestinal cancers, 0·65, 0·54—0·78, p<0·0001), and benefit increased (interaction p=0·01) with scheduled duration of trial treatment (≥7·5 years: all solid cancers, 0·69, 0·54—0·88, p=0·003; gastrointestinal cancers, 0·41, 0·26—0·66, p=0·0001). The latent period before an effect on deaths was about 5 years for oesophageal, pancreatic, brain, and lung cancer, but was more delayed for stomach, colorectal, and prostate cancer. For lung and oesophageal cancer, benefit was confined to adenocarcinomas, and the overall effect on 20-year risk of cancer death was greatest for adenocarcinomas (HR 0·66, 0·56—0·77, p<0·0001). Benefit was unrelated to aspirin dose (75 mg upwards), sex, or smoking, but increased with age—the absolute reduction in 20-year risk of cancer death reaching 7·08% (2·42—11·74) at age 65 years and older.

Interpretation

Daily aspirin reduced deaths due to several common cancers during and after the trials. Benefit increased with duration of treatment and was consistent across the different study populations. These findings have implications for guidelines on use of aspirin and for understanding of carcinogenesis and its susceptibility to drug intervention.

Commenti

Post popolari in questo blog

Have mymonero some problems ?

Hello, this is user pandher from BTCtalk. I have been a follower and holder of Monero since 2014 when the first bitmonero thread appeared on BTCtalk. Since that thread i knew Monero was the only one worth following. The professionalism and honesty of the dev team was a rare sight in that shitcoin madness. Checking the Monero reddit page and speculation thread had become a morning habit with me. I rarely missed reading both of these in these 2 years. I saw the community grow from a few hundred to a few thousand. It was so good to watch, to witness. Although i was mostly non vocal i felt myself as a part of this community. Reading AP's posts about the new world domination were exciting. But today i bid farewell to this wonderful community. All my Monero have been stolen Since zhalox posted about his lost Monero, i woke up from my slumber and created a cold wallet using GingerAle's paranoid method. Only to find out all my 4 MyMonero accounts were wiped on 3 september 2016. I...

Dove le molecole smettono di Ur­tarsi: viaggio nella coerenza Quantistica della Vita

C’era un momento, nella storia della biologia, in cui la vita veniva immaginata come un enorme tavolo da biliardo. Molecole che si urtano. Collisioni casuali. Reazioni che accadono perché, semplicemente, qualcosa colpisce qualcos’altro nel modo giusto. Funzionava. Più o meno. Poi, lentamente, qualcosa ha iniziato a incrinarsi. Non perché quella visione fosse sbagliata, ma perché era incompleta. Troppo rumorosa. Troppo cieca. Troppo… inefficiente per spiegare ciò che osservavamo davvero. Perché dentro le cellule accadevano cose strane. Troppo veloci. Troppo precise. Troppo coordinate. Come se, invece di urtarsi alla cieca, le particelle… sapessero. Immagina di entrare dentro una cellula. Non troverai caos. Non troverai disordine. Troverai elettroni che scorrono come una valuta invisibile, scambiata con una precisione che sfida l’intuizione. Non saltano semplicemente da una molecola all’altra: a volte attraversano barriere che, secondo la fisica classica, non dovrebbero poter...

Ingegneria del contesto per l'intelligenza artificiale avanzata

  Quando si parla di IA generativa, il dibattito pubblico si concentra spesso su due aspetti: la potenza del modello e la qualità dei prompt. Tuttavia, tra questi due poli si trova un'area meno discussa ma cruciale:  il contesto  . Non stiamo parlando solo di "informazioni extra" per il modello, ma dell'architettura logica e operativa che determina il modo in cui l'intelligenza artificiale interpreta, collega e utilizza i dati per fornire risultati accurati e coerenti. È qui che entra in gioco  l'ingegneria del contesto  : l'arte (e la scienza) di progettare, organizzare e ottimizzare il contesto di un Large Language Model (LLM) per guidarlo verso risposte più affidabili, precise e utili. Perché l'ingegneria del contesto è importante Un LLM non "capisce" il mondo come gli esseri umani. Elabora modelli statistici in base agli input che riceve e ai dati di training.  Il contesto  è la combinazione di istruzioni, esempi, dati di supporto e rifer...